Hengrui Medicine: Injection SHR-A2102 receives clinical trial approval.

Hengrui Pharmaceuticals announced that its subsidiaries Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Hengrui Pharmaceuticals Co., Ltd. have received approval from the National Medical Products Administration for the clinical trial of injection SHR-A2102. The injection SHR-A2102 is a targeted antibody-drug conjugate developed by the company with proprietary intellectual property targeting Nectin-4, with its payload being a topoisomerase I inhibitor. Clinical trials will be conducted soon.